At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
REPL Replimune Group Inc.
Closed Memorial Day 05-22 16:00:00 EDT
4.91
-0.31
-5.94%
盘后4.95
+0.04+0.81%
19:46 EDT
High5.25Low4.87Vol2.96M
Open5.25D1 Closing5.22Amplitude7.28%
Mkt Cap405.43MTradable Cap245.35MTotal Shares82.57M
T/O14.74MT/O Rate5.92%Tradable Shares49.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Replimune Group call volume above normal and directionally bullish
TIPRANKS  ·  05-21
Replimune Group call volume above normal and directionally bullish
Biotech Investors Are Tuning Out the MAHA Chaos -- Heard on the Street -- WSJ
Dow Jones  ·  05-20
Biotech Investors Are Tuning Out the MAHA Chaos -- Heard on the Street -- WSJ
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms
Reuters  ·  05-14
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms
BUZZ-U.S. STOCKS ON THE MOVE-Nebius, US chipmakers, Assertio Holdings
Reuters  ·  05-13
BUZZ-U.S. STOCKS ON THE MOVE-Nebius, US chipmakers, Assertio Holdings
BUZZ-U.S. STOCKS ON THE MOVE-Tyler Technologies, Autodesk, Illumina
Reuters  ·  05-13
BUZZ-U.S. STOCKS ON THE MOVE-Tyler Technologies, Autodesk, Illumina
BUZZ-Replimune, uniQure rise; FDA commissioner Makary plans to resign
Reuters  ·  05-13
BUZZ-Replimune, uniQure rise; FDA commissioner Makary plans to resign
Trump says US FDA Commissioner Makary is out
Reuters  ·  05-13
Trump says US FDA Commissioner Makary is out
Replimune Group Shares Slip 2.9% Premarket After Nearly 22% Gain in Previous Session
THOMSON REUTERS  ·  05-11
Replimune Group Shares Slip 2.9% Premarket After Nearly 22% Gain in Previous Session
Replimune Climbs on Report of Makary's Possible Ouster From FDA
Dow Jones  ·  05-09
Replimune Climbs on Report of Makary's Possible Ouster From FDA
Replimune jumps on news FDA chief behind RP1 rejection may be removed
TIPRANKS  ·  05-09
Replimune jumps on news FDA chief behind RP1 rejection may be removed
BUZZ-Replimune surges after report FDA chief Makary may be ousted
Reuters  ·  05-09
BUZZ-Replimune surges after report FDA chief Makary may be ousted
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:09 PM
Reuters  ·  05-09
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:09 PM
BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
Reuters  ·  05-06
BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel
FDA Commissioner Makary defends agency's decision on Replimune's drug
Reuters  ·  05-05
FDA Commissioner Makary defends agency's decision on Replimune's drug
Replimune Shares Fall 5% After FDA Commissioner Marty Makary Defends Agency's Decision on Co's Cancer Drug
THOMSON REUTERS  ·  05-05
Replimune Shares Fall 5% After FDA Commissioner Marty Makary Defends Agency's Decision on Co's Cancer Drug
Rpt- FDA's Makary on Replimune Says Three Indepndent Teams Arrived at the Same Conclusions - CNBC
THOMSON REUTERS  ·  05-05
Rpt- FDA's Makary on Replimune Says Three Indepndent Teams Arrived at the Same Conclusions - CNBC
FDA's Makary on Replimune's Drug Says IF the Clinical Trials Show That It Works, It's Going to GET Approved - CNBC
THOMSON REUTERS  ·  05-05
FDA's Makary on Replimune's Drug Says IF the Clinical Trials Show That It Works, It's Going to GET Approved - CNBC
Replimune to present IGNYTE trial survival data at ASCO annual meeting
Reuters  ·  04-27
Replimune to present IGNYTE trial survival data at ASCO annual meeting
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire  ·  04-27
Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection
Reuters  ·  04-23
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection
No data available

Introduction

Company Name.
Replimune Group Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Issue price:
--